Bone Biologics Corp (BBLG): Price and Financial Metrics

Bone Biologics Corp (BBLG): $0.57

0.05 (-8.06%)

POWR Rating

Component Grades








BBLG Price/Volume Stats

Current price $0.57 52-week high $32.40
Prev. close $0.62 52-week low $0.55
Day low $0.55 Volume 153,800
Day high $0.60 Avg. volume 156,558
50-day MA $0.90 Dividend yield N/A
200-day MA $5.07 Market Cap 1.79M

BBLG Stock Price Chart Interactive Chart >

Bone Biologics Corp (BBLG) Company Bio

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

BBLG Latest News Stream

Event/Time News Detail
Loading, please wait...

BBLG Latest Social Stream

Loading social stream, please wait...

View Full BBLG Social Stream

Latest BBLG News From Around the Web

Below are the latest news stories about BONE BIOLOGICS CORP that investors may wish to consider to help them evaluate BBLG as an investment opportunity.

Bone Biologics Provides Scientific Update on NB1 Bone Graft Device

BURLINGTON, Mass., September 26, 2023--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, provides an update on its clinical development initiatives with its NB1 bone graft device.

Yahoo | September 26, 2023

Insider Buying: CFO Deina Walsh Acquires 8,000 Shares of Bone Biologics Corp (BBLG)

On September 13, 2023, Deina Walsh, the Chief Financial Officer (CFO) of Bone Biologics Corp (NASDAQ:BBLG), made a significant insider purchase of 8,000 shares of the company.

Yahoo | September 15, 2023

CEO Jeff Frelick Buys 9,500 Shares of Bone Biologics Corp (BBLG)

On September 11, 2023, Jeff Frelick, the CEO of Bone Biologics Corp (NASDAQ:BBLG), purchased 9,500 shares of the company, marking a significant insider buying activity.

Yahoo | September 13, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting the final day of trading this week with a dive into the biggest pre-market stock movers worth watching for Friday!

William White on InvestorPlace | August 18, 2023

BBLG Advances Crucial Technology and Solidifies Funding

By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) recently announced that it has received approval to begin pilot clinical trials with NB1 in spinal fusion patients. The approval was given by the Human Research Ethics Committee and the trials will take place in Australia. This is an important and exciting step for Bone as the study will evaluate the

Yahoo | August 15, 2023

Read More 'BBLG' Stories Here

BBLG Price Returns

1-mo -15.00%
3-mo -60.69%
6-mo -92.69%
1-year -98.26%
3-year N/A
5-year N/A
YTD -90.94%
2022 -94.04%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!